Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080327 · ClinicalTrials.gov registry record · Phase 4
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
A Phase 4 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 4
- Development phase
- 370
- Enrollment target
NCT00080327 is a Phase 4 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 370 participants.
The verdict
NCT00080327, a Phase 4 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 370 participants
- Enrollment target
Study Summary
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
Interventions
- DRUG Placebo
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2003-11 |
| Est. Completion | 2004-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080327
The ClinicalTrials.gov registry entry for NCT00080327 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00080327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00080327 about?
NCT00080327 is a clinical study titled "Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia". A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
What is the current status of trial NCT00080327?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 370 participants. The study started on 2003-11. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00080327?
The interventions under investigation include: Placebo (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00080327?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.